Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_4
1
25%
Ph phase_3
2
50%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Not yet recruiting2
Enrolling by invitation1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

not_yet_recruiting250%
enrolling_by_invitation125%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
enrolling_by_invitationphase_3

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

NCT07258680
not_yet_recruitingphase_3

Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

NCT07178457
not_yet_recruitingphase_4

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

NCT06761911
unknownphase_2

BV After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03540849

Clinical Trials (4)

Showing 4 of 4 trials
NCT07258680Phase 3

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Enrolling By Invitation
NCT07178457Phase 3

Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

Not Yet Recruiting
NCT06761911Phase 4

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Not Yet Recruiting
NCT03540849Phase 2

BV After Allogeneic Hematopoietic Stem Cell Transplantation

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4